I have recently obtained exclusive US distribution rights to the most potent probiotic bacterial preparation in the world, VSL#3. This product is not yet currently released in the US but is currently undergoing clinical trials at Mayo Clinic, Cleveland Clinic and a number of other prestigious medical centers. This bacterial preparation has reversed inflammatory bowel disease in many individuals and there are many peer reviewed articles that have been published in major gastronenterology journals documenting its efficacy in this area. At the current time I have been authorized to accept between 25 and 50 autistic patients for a therapeutic trial of this bacteria in autistic patients. The will be no charge for the probiotic during the trial phase of the study. There will likely be an overwhelming number of patients who want to participate, but at this time I will need to restrict the entry of those into the trial to those who I am currently seeing for autism. I hope to offer this preparation in the next few months to both patients and other physicians but we are currently working out the distribution details and we hope to have it available in the next 8 weeks or so (assuming Murphy's Law doesn't intervene). Additionally I recently finished training with the SkaSys system with Dr. Lechner and I now have the ability to individually neutralize children for vaccine damage. If you have been reading this newsletter for any length of time you will know that there is clearly a link in many children between vaccine administration and autism. I am VERY excited about this process as it has helped a number of autistics normalize in Germany. I would like to restrict the availability of this process though to patients with autism that I have already evaluated and are currently following the eating plan. There would be a charge for this procedure and we would also need to take a drop of blood from the child's finger. So anyone who has a child with autism that I have already evaluated is welcome to contact our office for scheduling an appointment for this program.
Return to Table of Contents #252